Published: Tuesday, May 10, 2011 Last Updated: Tuesday, May 10, 2011
Major biopharmaceutical companies continued to demonstrate their confidence in the Gyros immunoassay platform, with existing accounts investing in additional Gyrolab™ workstations at different sites on both sides of the Atlantic.
Full access to this article is for registered users only. Registration is free-of-charge and allows access to all content on our web communities.
Already registered? Then please log in at the top of the page.